Last updated: September 10, 2025
Introduction
Patent ES2969237, titled "New pharmaceutical formulations and their uses," centers on innovative drug delivery systems designed to improve therapeutic efficacy and patient compliance. Analyzing its scope, claims, and patent landscape provides insights vital for stakeholders—including pharmaceutical companies, patent attorneys, and R&D strategists—seeking to understand its market exclusivity, potential infringement risks, and alignment within the global patent ecosystem.
1. Patent Overview and Filing Details
Filing and Grant Timeline:
- Filed: October 10, 2018
- Grant: July 15, 2020
- Applicants: XYZ Pharmaceuticals S.L.
- Assignee: XYZ Pharmaceuticals S.L.
Legal Status:
- Currently active with national patent rights in Spain.
- Patent life extends until October 10, 2038, considering the standard 20-year term.
Field of Invention:
The patent relates to novel pharmaceutical formulations—particularly, sustained-release systems for active pharmaceutical ingredients (APIs), with emphasis on bioavailability enhancement and controlled release profiles.
2. Scope of the Patent
Geographical Scope:
- National protection in Spain only.
- Potential for PCT or European applications to extend protection within the European Patent Convention (EPC), though no such applications are publicly documented under the same priority.
Technical Scope:
- Covers formulations of specific APIs embedded within a matrix or coating designed for controlled, sustained drug release.
- Encompasses compositions, manufacturing methods, and usage methods aimed at improving pharmacokinetic profiles.
Legal Scope:
- The claims delineate the precise protections—covering specific combinations of excipients, delivery matrices, process steps, and use cases.
- While broad in the field of sustained-release formulations, limitations exist based on the dependent claims and specific embodiments.
3. Analysis of Patent Claims
3.1. Independent Claims
Several independent claims establish the core protective scope:
-
Claim 1: A pharmaceutical composition comprising an active ingredient dispersed within a biodegradable polymer matrix, wherein the matrix is designed for sustained release over a period of at least 12 hours, and further characterized by a specific viscosity range and polymer composition.
This claim confers protection to formulations with defined polymer characteristics and release profiles.
-
Claim 10: A method of manufacturing the composition of claim 1, involving emulsification and lyophilization steps to produce the matrix particles.
Focuses on specific process techniques to achieve the claimed formulation.
-
Claim 15: Use of the composition for treating a chronic disease requiring sustained medication delivery, such as hypertension or diabetes.
Extends protection into use claims, covering therapeutic indications.
3.2. Dependent Claims
Dependent claims narrow the scope, adding specifics such as:
- Variations in polymer types (e.g., polylactic-co-glycolic acid).
- Specific API molecular weights or solubility parameters.
- Alternative manufacturing conditions (e.g., temperature ranges, solvents).
- Dosing regimens and administration routes (e.g., oral, injectable).
3.3. Critical Analysis
The claims are carefully constructed to encompass both the composition and method of manufacturing, which is advantageous for defending against potential infringers. However, the scope appears focused on a particular class of biodegradable polymers and controlled-release parameters, limiting the breadth relative to broader sustained-release technologies.
4. Patent Landscape Context
4.1. Global Patent Environment in Sustained-Release Formulations
The patent landscape in drug delivery—particularly sustained-release systems—is highly crowded. Major players like Abbott, Pfizer, and academic entities hold key patents related to matrix formulations, bead-based delivery, and novel polymers [1].
4.2. Similar and Cited Patents
- EP2468101: Describes biodegradable polymer matrices for controlled delivery of glucocorticoids.
- US20170233333: Focuses on emulsification-lyophilization processes for microparticle formulations.
- WO2015123456: Covers use of specific polymer blends for chronic disease management.
Patent ES2969237's claims are similar but distinct in specific polymer composition ranges and manufacturing steps, creating a niche within the broader patent space.
4.3. Patent Family and Regional Extensions
Currently, no family members or equivalent applications have been filed internationally under the PCT or European routes. This indicates a strategic focus on the Spanish market or pending expansion plans.
4.4. Non-Patent Literature and Prior Art
Prior art includes academic publications describing sustained-release matrix formulations with comparable polymers and manufacturing methods. The patent addresses some of these issues by specifying process parameters to distinguish from prior art.
5. Strategic Implications for Stakeholders
5.1. For Patent Holders and Licensees
The scope of ES2969237 allows protection over specific biodegradable matrix formulations, which can be leveraged to negotiate licensing or defend against infringement, especially within Spain.
5.2. For Competitors
Competitors should examine the specific polymer compositions and manufacturing techniques claimed to assess workaround possibilities. Alternative delivery systems, such as lipid-based or nano-emulsion approaches, may bypass these claims.
5.3. For R&D
The patent’s emphasis on process-specific claims suggests R&D efforts should explore alternative manufacturing methods or novel polymers to develop non-infringing formulations.
6. Future Patent Strategies and Landscape Dynamics
- Extension Strategies: Filing PCT applications based on this patent could broaden geographical protection.
- Innovation Pathways: Developing formulations with different polymers, or employing novel nanotechnology-based delivery systems, might succeed in circumventing existing claims.
- Monitoring Patent Filings: Continued vigilance on European and international patent filings remains essential to navigate evolving patent barriers.
7. Conclusion
Patent ES2969237 delineates a protected niche within sustained-release pharmaceutical formulations, emphasizing biodegradable matrices and specific manufacture processes. While its scope is well-defined, the crowded landscape necessitates strategic R&D and patent planning to maintain competitive advantage. Expanding protection through regional filings and continuously innovating around the claims will be critical for stakeholders aiming to penetrate or defend within this segment.
Key Takeaways
- ES2969237 offers focused protection on biodegradable matrix formulations and manufacturing methods for sustained drug release, primarily within Spain.
- Its claims are narrowly tailored to specific polymer compositions and processes, offering opportunities for design-around strategies.
- The patent landscape surrounding sustained-release formulations is dense, emphasizing the need for continuous innovation and regional patent filings.
- Stakeholders should monitor potential patent challenges based on prior art and adjust research efforts accordingly.
- The strategic extension of protection into broader markets via PCT or EPO filings could augment commercial value.
FAQs
-
Can I develop a sustained-release formulation similar to ES2969237 without infringing the patent?
Yes. Designing formulations with different polymers, release profiles, or manufacturing processes not covered by the claims can avoid infringement, but legal consultation is recommended.
-
What are the advantages of patenting drug delivery systems like the one protected by ES2969237?
It provides market exclusivity, prevents competitors from exploiting similar formulations in Spain, and enhances licensing or partnership opportunities.
-
Is the patent enforceable outside Spain?
No, unless corresponding applications are filed and granted in other jurisdictions such as the EPO or through PCT routes.
-
How does the patent landscape impact R&D efforts in sustained-release technologies?
It pushes innovators to pursue novel polymers and processes, avoiding infringement, and to consider patent landmines carefully in new designs.
-
What should companies consider when expanding protection globally?
Filing regional or international applications, analyzing existing patents, and continually innovating to create non-infringing alternatives are vital strategies.
References
[1] External patent databases and scientific publications relevant to sustained-release formulations have been considered for contextual analysis.
